26 results on '"Wiklik, Katarzyna"'
Search Results
2. CDK8 kinase—An emerging target in targeted cancer therapy
3. Abstract 2647: RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo
4. Abstract P5-17-13: Selective CDK8/CDK19 inhibitor RVU120 demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo
5. Abstract 1018: SEL120, a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in AML
6. Abstract 3656: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
7. Abstract 6217: Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance
8. Abstract 4532A: Development of selective small molecule STING agonists suitable for systemic administration
9. SEL120, a potent and specific inhibitor of CDK8, as a potential treatment of acute myeloid and lymphoblastic leukemias
10. CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human AML Models
11. SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial
12. CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation
13. Abstract 1306: SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia
14. Abstract 4983: Discovery and characterization of next-generation small molecule direct STING agonists
15. 5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors
16. Synthesis of amide and sulfonamide substituted N-aryl 6-aminoquinoxalines as PFKFB3 inhibitors with improved physicochemical properties
17. Discovery and Structure–Activity Relationships of N ‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors
18. CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models
19. Abstract 5829: CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of various transcriptional programs involved in maintenance of leukemia stem cells
20. Abstract 2174: Inhibition of CDK8 kinase with SEL120-34A allows for a personalized approach in AML
21. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains
22. Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy
23. Abstract 696: Development of selective CDK8 inhibitors for colorectal cancer and mantle cell lymphoma treatment.
24. Abstract 2160: Development of selective MELK kinase inhibitors for cancer treatments.
25. Abstract 3245: Identification of potent, dual PIM/FLT3 kinase inhibitors for AML treatment.
26. Discovery and Structure-Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.